Literature DB >> 2117504

Reductive metabolism of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines.

A Cahill1, I N White.   

Abstract

The cellular and microsomal reductive metabolism of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) was studied aerobically and anaerobically in rat (JB1, BL8, Walker) mouse (3T3) and human (HepG2) derived cell lines. In all cases rates or reduction to the mono-N-oxide (SR 4317) were greater under anaerobic than aerobic conditions when determined using HPLC with UV and fluorescence detection. Of the rat derived cells, a transformed liver epithelial line (JB1) showed the greatest cellular and microsomal rates of reduction while Walker 256 carcinoma cells showed the lowest. Microsomal reduction of SR 4233 was the highest in preparations from rat liver but carbon monoxide did not inhibit the reaction, suggesting cytochrome P450 was not involved. Purified cytochrome P450 reductase could carry out the reduction of SR4233. Rates of reduction of SR4233 in microsomal preparations from the cell lines and in rat liver nuclei correlated with activities of cytochrome P450 reductase. Activation of SR 4233 to cause cellular DNA damage was measured using unscheduled DNA synthesis as an index. Under anaerobic conditions, SR 4233 caused a dose-dependent increase in unscheduled DNA synthesis. Only a slight increase occurred following aerobic incubation. No increase was seen using the reduced metabolites SR 4317 or SR 4330. Of the cell lines studied, Walker cells showed the highest induction of unscheduled DNA synthesis. It was concluded that rates of reduction of SR 4233 did not necessarily reflect the potential DNA-damaging effects of this compound.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117504     DOI: 10.1093/carcin/11.8.1407

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  10 in total

1.  Acute lesions in rats caused by 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) or nitromin: a comparison with rates of reduction in microsomal systems from target organs.

Authors:  I N White; A Cahill; A Davies; P Carthew
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

2.  Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.

Authors:  A V Patterson; M P Saunders; E C Chinje; D C Talbot; A L Harris; I J Strafford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

Authors:  E C Chinje; A V Patterson; M P Saunders; S D Lockyer; A L Harris; I J Stratford
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

4.  Kinetics of Flavoenzyme-Catalyzed Reduction of Tirapazamine Derivatives: Implications for Their Prooxidant Cytotoxicity.

Authors:  Aušra Nemeikaitė-Čėnienė; Jonas Šarlauskas; Violeta Jonušienė; Audronė Marozienė; Lina Misevičienė; Aliaksei V Yantsevich; Narimantas Čėnas
Journal:  Int J Mol Sci       Date:  2019-09-17       Impact factor: 5.923

Review 5.  The experimental development of bioreductive drugs and their role in cancer therapy.

Authors:  P Workman; I J Stratford
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

6.  Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.

Authors:  J Wang; K A Biedermann; C R Wolf; J M Brown
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

Review 7.  SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.

Authors:  J M Brown
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

8.  Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.

Authors:  P L Olive
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

9.  Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).

Authors:  A V Patterson; H M Barham; E C Chinje; G E Adams; A L Harris; I J Stratford
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

10.  Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations.

Authors:  S Khan; P J O'Brien
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.